摘要
目的了解四川省金黄色葡萄球菌对万古霉素、利奈唑胺耐药情况,为临床抗感染治疗提供参考依据。方法收集四川省71所医院2011—2015年临床分离的金黄色葡萄球菌、耐甲氧西林金黄色葡萄球菌(MRSA),并计算每年万古霉素与利奈唑胺对金黄色葡萄球菌、MRSA的最低抑菌浓度(MIC)值。结果 5年共收集51 976株金黄色葡萄球菌,包括MRSA14 361株,MRSA检出率由2011年的36.02%下降至2015年的25.56%,呈下降趋势(χ2=160.72,P<0.05)。2011—2015年万古霉素对金黄色葡萄球菌的MIC50值分别为:1、0.5、0.5、1、1μg/mL,MIC90值由1μg/mL上升至2μg/mL;利奈唑胺MIC50值均为2μg/mL,MIC90值由2μg/mL上升至4μg/mL。2011—2015年万古霉素对MRSA的MIC50、MIC90值变化较明显,分别由0.5、1μg/mL上升至2μg/mL;利奈唑胺MIC50值均为2μg/mL,MIC90值由2μg/mL上升至4μg/mL。结论 MRSA的检出率有下降趋势,但万古霉素、利奈唑胺对其MIC50及MIC90值总体有上升趋势,需继续加强细菌耐药监测,为临床合理应用抗菌药物提供帮助。
Objective To investigate the resistance of Staphylococcus aureus (S.aureus) to vancomycin and linezolid in Sichuan Province, and provide reference for clinical anti-infection treatment.Methods S.aureus and methicillin-resistant S.aureus(MRSA) from 71 hospitals in Sichuan Province in 2011-2015 were collected, minimum inhibitory concentration(MIC) values of vancomycin and linezolid against S.aureus and MRSA in each year were calculated.Results A total of 51 976 strains of S.aureus were collected in 5 years, 14 361 of which were MRSA, isolation rate of MRSA decreased from 36.02% in 2011 to 25.56% in 2015, which showed a downward trend (x2=160.72,P〈0.05).From 2011 to 2015, MIC50 of vancomycin against S.aureus were 1, 0.5, 0.5, 1, and 1μg/mL respectively,MIC90 increased from 1μg/mL to 2μg/mL;the mean MIC50 of linezolid was 2μg/mL,MIC90 increased from 2μg/mL to 4μg/mL.Change in MIC50 and MIC90 of vancomycin against MRSA in 2011-2015 were obvious, which increased from 0.5, 1μg/mL to 2μg/mL respectively;the mean MIC50 of linezolid was 2μg/mL,MIC90 increased from 2μg/mL to 4μg/mL.Conclusion The isolates rate of MRSA had a decreasing trend,but there is a upward trend of MIC50 and MIC90 of vancomycin and linezolid against MRSA, bacterial resistance surveillance needs to be strengthened to provide evidence for rational clinical antimicrobial therapy.
出处
《中国感染控制杂志》
CAS
北大核心
2017年第9期807-809,824,共4页
Chinese Journal of Infection Control
关键词
金黄色葡萄球菌
耐甲氧西林金黄色葡萄球菌
万古霉素
利奈唑胺
最低抑菌浓度
MRSA
Staphylococcus aureus
methicillin-resistant Staphylococcus aureus
MRSA
vancomycin
linezolid
minimum inhibitory concentration